SCHEMBL2384032

SCHEMBL2384032

CCOC(=O)c1ccc(NN(C)C(C)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
NPC1 O15118 4/20 0.56
TP53 P04637 1/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 2/20 0.55
RECQL P46063 1/20 0.55
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 4/20 0.53
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CA12 O43570 1/20 0.53
ESR1 P03372 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
ESR2 Q92731 1/20 0.53
CA14 Q9ULX7 1/20 0.53
MEN1 O00255 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28579351 0.81 RAB9A (0.63) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL12124929 0.78 RAB9A (0.69) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL87450 0.77 CA1 (0.83) RAB9ASMN1; SMN2NPC1HPGDRECQL
SCHEMBL4289783 0.77 HPGD (0.71) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL3233695 0.76 HPGD (0.65) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL1500512 0.76 HPGD (0.65) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL4771057 0.76 TP53 (0.46) SMN1; SMN2NPC1TP53POLBTSHR
SCHEMBL2662692 0.76 RAB9A (0.54) RAB9ASMN1; SMN2NPC1TP53POLB
SCHEMBL2383994 0.76 TDP1 (0.52) RAB9ASMN1; SMN2NPC1POLBHPGD
SCHEMBL4286426 0.76 CA12 (0.58) RAB9ASMN1; SMN2NPC1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 US disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP RAB9A 2572/4885SMN1; SMN2 1100/4885NPC1 2579/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD RAB9A 1985/4885SMN1; SMN2 563/4885NPC1 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.